Unique ID issued by UMIN | UMIN000053365 |
---|---|
Receipt number | R000060908 |
Scientific Title | Exploratory study of the effect of oligosaccharide intake on gut microbiota, blood marker, and physical condition |
Date of disclosure of the study information | 2024/01/19 |
Last modified on | 2024/11/27 19:39:44 |
Exploratory study of the effect of oligosaccharide intake on gut microbiota, blood marker, and physical condition
Exploratory study of the effect of oligosaccharide intake on gut microbiota, blood marker, and physical condition
Exploratory study of the effect of oligosaccharide intake on gut microbiota, blood marker, and physical condition
Exploratory study of the effect of oligosaccharide intake on gut microbiota, blood marker, and physical condition
Japan |
Healthy adult
Not applicable |
Others
NO
To examine the effect of four weeks of oligosaccharide intake on gut microbiota, blood marker, and physical condition
Safety,Efficacy
Exploratory
Pragmatic
Not applicable
gut microbiota
fecal organic acid concentration, fecal bile acid concentration, blood marker, physical conditions (height, body weight, BMI, muscle mass, body fat mass, body fat percentage, blood pressure), and incidence of adverse events
Interventional
Single arm
Non-randomized
Open -no one is blinded
Self control
NO
NO
Institution is not considered as adjustment factor.
NO
No need to know
1
Prevention
Food |
Oral ingestion of oligosaccharide for four weeks
Not applicable |
Not applicable |
Male and Female
1.Those who provided specimens in which oligosaccharide increased the number of useful bacteria in vitro
2.Those who belongs to R&D division on the date of consent
3.Those who have received sufficient explanation about the purpose and content of this study, have the consent ability and good understandings, and have agreed voluntarily to participate in the study
1.Those who have participated in other intervention studies in the month prior to screening or who plan to participate in other intervention studies during the period from screening to the end of the intake period
2.Those who have a history of gastric or lower gastrointestinal tract surgery excluding hemorrhoids
3.Those who have a barium stomach X-ray, small or large intestine endoscopy, or bowel cleansing at a clinic or at home in the month prior to screening or who plan to have these procedures during this study
4.Those who have taken, ingested, or used drugs that may affect the study at least once a week in the month prior to screening, or who plan to take, ingest, or use these drugs at least once during the study
5.Those who plan to travel abroad, travel for more than one week, or go on a business trip during the period from one week prior to the intake period to the end of the intake period
6.Those with lactose intolerance
7.Those with milk allergy
8.Females who are pregnant and/or lactating
9.Those judged as unsuitable for the study by the principal investigator or research physician for other reasons
60
1st name | Seiya |
Middle name | |
Last name | Makino |
Meiji Co., Ltd.
R&D Division
192-0919
1-29-1 Nanakuni, Hachiouji, Tokyo
042-632-5838
seiya.makino@meiji.com
1st name | Seiya |
Middle name | |
Last name | Makino |
Meiji Co., Ltd.
R&D Division
192-0919
1-29-1 Nanakuni, Hachiouji, Tokyo
042-632-5838
seiya.makino@meiji.com
Meiji Co., Ltd.
Meiji Co., Ltd.
Profit organization
Meiji Institutional Review Board
1-29-1 Nanakuni, Hachiouji, Tokyo
042-632-5900
MEIJI.IRB@meiji.com
NO
2024 | Year | 01 | Month | 19 | Day |
Unpublished
25
Completed
2023 | Year | 12 | Month | 14 | Day |
2023 | Year | 12 | Month | 19 | Day |
2024 | Year | 01 | Month | 26 | Day |
2024 | Year | 06 | Month | 30 | Day |
2024 | Year | 01 | Month | 16 | Day |
2024 | Year | 11 | Month | 27 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000060908